403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Oncolytics Biotech Inc
(MENAFN- Baystreet) 09:50 AM EST - Oncolytics Biotech Inc: Announces that a Type C meeting with the U.S. Food and Drug Administration has resulted in alignment on the design of a pivotal clinical study to support approval of pelareorep in patients with unresectable metastatic squamous cell carcinoma of the anal canal.“We want to thank the FDA for its very clear guidance and helping us create an efficient pathway for pelareorep in a disease that is desperate for new treatments,” said Jared Kelly, Chief Executive Officer of Oncolytics. Oncolytics Biotech Inc
shares N are trading up $0.02 at $1.05.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
Comments
No comment